PhilipOLivingstonMD

Professor, Medicine, Weill Cornell Medical College, Retired 2011 Chief Scientific Officer, MabVax Therapeutics Inc, San Diego, CA. Chief Scientific Officer, Adjuvance Technologies, NYC, NY.

Join to view full profile

Dr. Livingston is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Livingston's full profile

Already have an account?

Office
1275 York Ave
New York, NY 10065
Phone+1 646-227-3275

Education & Training

NYU Grossman School of MedicineResidency, Internal Medicine, 1971 - 1972
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1969 - 1971
Harvard Medical SchoolClass of 1969

Certifications & Licensure

NY State Medical License 1970 - 2021
American Board of Allergy and Immunology Allergy & Immunology

Awards, Honors, & Recognition

Fellow (FACP) American College of Physicians, 2006

Clinical Trials

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 1999 Jun 01
Completed
Phase 1

Publications & Presentations

PubMed

22 citations
Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol.
Alberto Fernández-Tejada, Eric K. Chea, Constantine George, Jeffrey Gardner, Philip O. Livingston
Bioorganic & Medicinal Chemistry. 2014-11-01
58 citations
Development of a minimal saponin vaccine adjuvant based on QS-21
Alberto Fernández-Tejada, Eric K. Chea, Constantine George, Nagavarakishore Pillarsetty, Jeffrey Gardner
Nature Chemistry. 2014-07-01
50 citations
Applying PET to Broaden the Diagnostic Utility of the Clinically Validated CA19.9 Serum Biomarker for Oncology
Nerissa Viola-Villegas, Samuel L. Rice, Sean Carlin, Xiaohong Wu, Michael J. Evans
Journal of Nuclear Medicine. 2013-11-01

Press Mentions

MabVax Therapeutics Grants License to Y-mAbs TherapeuticsJuly 5th, 2018

Grant Support

Novel Adjuvant Discovery In Vaccine TherapyNational Institute Of Allergy And Infectious Diseases2010–2011
Characterization Of Human Antibodies To Sialyl-Lewis A (SLEA) Derived From PatienNational Cancer Institute2010
Immune MonitoringNational Cancer Institute2008–2009
Regulation By The Immune Response To Vaccines By BotanicalsNational Center For Complementary &Alternative Medicine2007–2009
Development Of Antibody And T-Cell Inducing VaccinesNational Cancer Institute2005–2009
Human Monoclonal Antibodies From Immunized Patient LymphocytesNational Cancer Institute2008
Pilot Trial With A Tetravalent Conjugate Vaccine Against Small Cell Lung CancerNational Cancer Institute2007
Regulation By Immune Response To Vaccine By BotanicalsNational Center For Complementary &Alternative Medicine2005–2006
Glycolipid And Protein Vaccines Against CancerNational Cancer Institute2000–2002
Clinical Trials With Active And Passive Immunotherapy Against Ovarian CancerNational Cancer Institute1998–2002
Clinical Trials With A Polyvalent Breast Cancer VaccineNational Cancer Institute1997–1999
Development Of Cancer VaccinesNational Cancer Institute1996–1999
Construction Of Vaccines Against Breast CancerNational Cancer Institute1994–1996
Immunization Of Melanoma Patients With GangliosidesNational Cancer Institute1987–1993
Immunization Of Melanoma Patients With GangliosidesNational Cancer Institute1991
Augmenting The Immunogenicity Of GangliosidesNational Cancer Institute1987–1989
Use Of Tumor Associated Antigens As ImmunogensNational Cancer Institute1985–1986
Treatment Of Suppressor Cell Activity In MelanomaNational Cancer Institute1985
Serological Response To Renal Cancer VaccinesNational Cancer Institute1985